Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations. NICE has separately evaluated cladribine for highly active multiple sclerosis in NICE ...

The following considerations around implementing the evidence generation process have been identified through working with system partners.

There is a commercial access agreement for ruxolitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Table 1 summarises the evidence gaps and ongoing studies that might address them. Information about evidence status is derived from the external assessment report. More information on the studies in ...

Table 1 summarises the evidence gaps and the evidence available to the committee when the guidance was published. Information about evidence status is derived from the external assessment report.

All the technologies that have been recommended for use in the NHS while more evidence is generated have some clinical evidence suggesting that they are comparable with current standard of care for ...